79313-01-2

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 2-(bromomethyl)-4,6-dimethyl(9CI) is used as a synthetic intermediate for the development of pharmaceuticals. Its unique structure allows for the creation of diverse drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, Pyridine, 2-(bromomethyl)-4,6-dimethyl(9CI) serves as a key component in the synthesis of various agrochemicals, contributing to the development of effective pest control agents and plant growth regulators.
Used in Fine Chemicals Production:
Pyridine, 2-(bromomethyl)-4,6-dimethyl(9CI) is utilized as a building block in the production of fine chemicals, which are high-purity chemicals used in various applications, including fragrances, flavors, and specialty chemicals.
Used in Corrosion Inhibitors:
Pyridine, 2-(bromomethyl)-4,6-dimethyl(9CI) is employed as a raw material in the formulation of corrosion inhibitors, which are essential in protecting metal surfaces from degradation in various industrial applications.
Used in Dyes and Pigments Industry:
Pyridine, 2-(bromomethyl)-4,6-dimethyl(9CI) is used in the synthesis of dyes and pigments, contributing to the development of vibrant colorants for various industries, such as textiles, plastics, and printing inks.

InChI:InChI=1/C8H10BrN/c1-6-3-7(2)10-8(4-6)5-9/h3-4H,5H2,1-2H3

Upstream product

• 108-75-8 2,4,6-trimethyl-pyridine 

Relevant academic research and scientific papers

A highly selective chemodosimeter for fast detection and intracellular imaging of Hg2+ ions based on a dithiocarbamate-isothiocyanate conversion in aqueous ethanol

A new naphthalene diimide-dithiocarbamate based fluorescence probe was synthesized and its fluorogenic behavior towards various metal ions was studied. Upon addition of various metal ions, the probe afforded an irreversible change only with Hg2+ ions in aqueous-ethanol media (4:1 v/v) with a fourfold enhancement of the fluorescence (Φ = 0.03 → 0.11) along with a distinct 43 nm blue shift of the emission maxima. The mechanism of the chemodosimetric behavior of the probe has been attributed to a Hg2+ induced transformation of a weakly fluorescent dithiocarbamate to a highly fluorescent isothiocyanate which has been characterized by a number of spectroscopic techniques and a crystal structure. Intracellular detection of Hg2+ ions was achieved using the probe. The Royal Society of Chemistry.

IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK

The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes, as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes

Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

Novel bisamidate phosphonate prodrugs

Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.

Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase

FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose or excess glycogen storage.